ArticleJournal of molecular histology2026
QiangGuYin-containing serum improves osteogenic differentiation via regulating osteoclast-derived exosomal miR-27b-3p.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Osteoclast-derived exosomes play a critical role in suppressing osteogenic differentiation, contributing to postmenopausal osteoporosis (PMOP). QiangGuYin (QGY), a traditional Chinese herbal formula, has demonstrated efficacy in alleviating PMOP progression. This study aimed to elucidate the mechanism by which QGY modulates osteoclast-derived exosome-mediated inhibition of osteogenesis. Exosomes were isolated from osteoclasts treated with QGY-containing serum or control serum. Bone marrow mesenchymal stem cells (BMMSCs) were used to evaluate osteogenic differentiation by Western blotting, alkaline phosphatase (ALP) activity assay, and Alizarin Red S staining. And qRT-PCR, Western blotting, immunofluorescence and immunohistochemistry were conducted to detect the expression of miR-27b-3p, DKK2 and the activation level of β-catenin pathway. Spearman's correlation analysis was used to evaluate relationships among exosomal miR-27b-3p, DKK2, β-catenin, and bone microarchitecture parameters. Osteoclast-derived exosomes significantly inhibited osteogenic differentiation, an effect reversed by QGY-containing serum. QGY-containing serum increased the abundance of miR-27b-3p in osteoclast-derived exosomes. MiR-27b-3p inhibitor abolished the protective effects of QGY. DKK2 was identified as a direct target of miR-27b-3p and was upregulated by osteoclast-derived exosomes but suppressed by QGY-containing serum. DKK2 overexpression blocked QGY-containing serum-mediated rescue of osteogenic differentiation and β-catenin pathway. In PMOP rats, QGY increased serum exosomal miR-27b-3p levels, suppressed DKK2 expression and enhanced β-catenin level in femoral tissues. Significant correlations were observed among exosomal miR-27b-3p, DKK2, β-catenin and bone quality indices. QGY-containing serum alleviates osteoclast-derived exosome-induced osteogenic differentiation inhibition via the miR-27b-3p/DKK2/β-catenin signaling, providing a mechanistic basis for the clinical application of QGY in PMOP treatment.
Indexed as
Identifiers
41961168What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.